Technology Development Mission at the Medical College of Wisconsin
The mission of the Office of Technology Development is to support and educate MCW faculty, postdoctoral fellows, interns, students and staff. The OTD facilitates the transfer of technology generated from research and clinical practices into commercial products that benefit MCW, our community and the public. The OTD engages inventors, as well as internal and external stakeholders to bring Patents to Patients®.
Who We Are
Kevin Boggs, MBA, PhD
Director, Office of Technology Development
Dr. Boggs provides principal leadership for the OTD, setting the strategic direction for the Office and managing key relationships. He has significant experience leading intellectual property licensing, negotiations, translational research and tech marketing efforts at organizations such as the University of Florida, University of Memphis, RTI International and AGTC. He serves on the Wisconsin Technology Council board and Co-Chairs the Wisconsin chapter of the Licensing Executives Society.
Landon Olp, PhD
Licensing Manager, Office of Technology Development
Dr. Olp is responsible for evaluating the commercial viability and patentability of MCW’s inventions as well as supporting the commercialization of MCW’s intellectual property. He brings both academic and industry experience to the OTD in biomedical research, product development, business development, and innovation methods. Landon received a bachelor’s degree in Cell and Molecular Biology from Concordia University, Nebraska and a PhD in Virology from the University of Nebraska—Lincoln.
Beginning with an invention disclosure submitted to OTD by the inventors, OTD evaluates the market potential of products and services using our in-house expertise as well as seeking confidential feedback from external experts with experience in IP law, business and medtech product development. We then provide our analysis of the technology along with our decision on whether we will retain the ownership of the IP and invest the resources into protecting and licensing it, revert the rights to the inventors or notify them that the technology, as disclosed, lacks sufficient data to be able to adequately evaluate the market opportunity. We are always glad to talk with MCW researchers about their ideas, even if they have not matured to the point of supporting an invention disclosure.
The process of bringing technologies to market is often iterative, but for many healthcare technologies that require significant investment and regulatory approval, the timelines generally resemble those shown below.
